According to a recent LinkedIn post from JenaValve Technology Inc, Scripps Health in San Diego has begun using the company’s Trilogy System, performing four procedures in its initial series. The post highlights that Trilogy is described as the first and only FDA-approved TAVR solution for aortic regurgitation in the U.S., targeting high‑surgical‑risk patients with symptomatic, severe disease.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests growing clinical adoption momentum for the Trilogy System, which could support revenue ramp-up if utilization expands across additional centers. Broader nationwide uptake, if realized, may strengthen JenaValve’s competitive position in the TAVR market niche focused on aortic regurgitation and potentially enhance the company’s attractiveness to strategic partners or acquirers in structural heart therapies.
By emphasizing collaboration with a prominent institution such as Scripps Health, the post underscores JenaValve’s strategy of aligning with leading heart teams to drive real‑world evidence generation. For investors, increased procedure volumes at reference centers may be an early indicator of physician confidence, supporting future reimbursement, market access, and scalability prospects for the Trilogy platform, subject to regulatory and clinical‑outcome considerations.